Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2025)

Avalo Therapeutics' Tax Provisions history spans 9 years, with the latest figure at $130000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 14.04% year-over-year to $130000.0; the TTM value through Dec 2025 reached $165000.0, up 44.74%, while the annual FY2025 figure was $165000.0, 44.74% up from the prior year.
  • Tax Provisions reached $130000.0 in Q4 2025 per AVTX's latest filing, up from $11000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $130000.0 in Q4 2025 to a low of -$200000.0 in Q2 2021.
  • Average Tax Provisions over 5 years is $6052.6, with a median of $8000.0 recorded in 2022.
  • The largest YoY upside for Tax Provisions was 1366.67% in 2024 against a maximum downside of 275.0% in 2024.
  • A 5-year view of Tax Provisions shows it stood at -$16000.0 in 2021, then surged by 150.0% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then grew by 14.04% to $130000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Tax Provisions are $130000.0 (Q4 2025), $11000.0 (Q3 2025), and $16000.0 (Q2 2025).